Imatinib Mesylate
Tyrosine kinase inhibitor specific for bcr-abl (IC50 = 38 nM) 1, PDGF-R (IC50 = 0.3 μM)1 and c-kit (IC50 = 0.1 μM) 2. It is a clinically useful anti-cancer drug approved for the treatment of chronic myelogenous leukemia, gastrointestinal stromal tumors as well as several other cancers 3. Lowers Amyloid Beta levels by indirect inhibition of gamma-secretase without inhibiting gamma-secretase processing of Notch1 4.
$38.00 – $171.00
-
Product Details
- Physical State: White powder
- Temperature Storage: -20°C
- Temperature Shipping: Ambient
- Molecular Mass: 589.7
-
References
1.Buchdunger, E., et al., (1996) Cancer Res., 56 : 100
2.Heinrich, et al., (2000) Blood, 96 : 925
3.Deininger, M., et al., (2003) Pharmacol. Rev., 55 : 401
4.Netzer, W.J., et al., (2017) Proc. Natl. Acad. Sci. USA, 114 : 1389
